More than 240 companies across the globe claim to have the required capabilities to offer variety of services on a contract basis

Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of ophthalmic drug developers have demonstrated a preference to outsource certain aspects of drug development and production operations to contract service providers.

To order this 375+ page report, which features 180+ figures and 195+ tables, please visit thishttps://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html

The USD 1.7 billion financial opportunity (by 2030) within the ophthalmic drugs contract manufacturing market has been analyzed across the following segments:

  • Type of product
  • Ophthalmic API
  • Ophthalmic drug FDF
  • Type of FDF manufactured
  • Solid
  • Semi-solid
  • Liquid / suspension
  • Type of primary packaging
  • Ampoule / vial 
  • Glass / plastic bottle
  • Ointment tube
  • Blister packing
  • Other forms
  • Scale of manufacturing
  • Clinical
  • Commercial
  • Company size
  • Small
  • Mid-sized
  • Large
  • Very large
  • Target disease indication
  • Age-related macular degeneration
  • Dry eye
  • Glaucoma
  • Other disease segments
  • Key geographical regions
  • North America (US, Canada and Mexico)
  • Europe (UK, Germany, France, Spain, Italy and rest of Europe)
  • Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific)
  • Rest of the world

The Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030.” report features the following companies, which we identified to be key players in this domain:

  • Akorn
  • Akums
  • Bal Pharma
  • Catalent
  • Cayman Chemical
  • Entod Pharmaceuticals
  • Farmigea
  • Glenmark Pharmaceuticals
  • Indiana Ophthalmics
  • Lomapharm
  • Medichem
  • Pillar5 Pharma
  • Recipharm
  • Salvat
  • Sterling Pharmaceutical Services
  • Sunways India

Table of Contents

1. Preface

2. Executive Summary


3. Introduction

4. Current Market Landscape

5. Company Competitiveness Analysis

6. Ophthalmic Drugs Contract Manufacturing in North America: Company Profiles

7. Ophthalmic Drugs Contract Manufacturing in Europe: Company Profiles

8. Ophthalmic Drugs Contract Manufacturing in Asia-Pacific: Company Profiles

9. Clinical Trial Analysis

10. Capacity Analysis

11. Demand Analysis

12. Market Forecast

13. Case Study: Comparison of Small Molecule and Large Molecule Ophthalmic Drugs / Therapies

14. SWOT Analysis

15. Survey Analysis

16. Executive Insights

17. Future Growth Opportunities

18. Appendix 1: List of Ophthalmic Medical Device Contract Manufacturers

19. Appendix 2: Tabulated Data

20. Appendix 3: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091Gaurav.Chaudhary@rootsanalysis.com

0 responses on "More than 240 companies across the globe claim to have the required capabilities to offer variety of services on a contract basis"

    Leave a Message

    Copyrights © 2020 Blavida.
    Skip to toolbar